Objective: To assess satisfaction with quality of care (QOC) and medication among patients with schizophrenia treated with either paliperidone palmitate (PP) or risperidone long-acting injectable (RLAI) in Community Behavioral Health Organizations (CBHO).
Methods: This descriptive analysis used the final dataset from REACH OUT, a concluded naturalistic prospective, observational study of 599 patients with schizophrenia treated with atypical long-acting atypical antipsychotics (LAI). Satisfaction with QOC received from CBHO sites was measured using a 4-point Likert scale. Medication satisfaction was measured with a validated single-item medication satisfaction questionnaire (MSQ). The change in satisfaction from enrollment to 1-year follow-up was assessed descriptively.
Results: PP (new=174; continuous=308) and RLAI (new=40; continuous=77) users who completed a 1-year follow-up period were analyzed. The patient characteristics and psychiatric histories appeared similar between both cohorts. Increased percentage of new (62.9% to 73.8%) and continuous users (74.4% to 76.1%) of PP, and new users of RLAI (55.6% to 61.9%) were "very-satisfied" with QOC from enrollment to 1-year. Meanwhile, there was indication of reduction in the "very satisfied" rating in the continuous users of RLAI. Patient satisfaction with current antipsychotic medication increased for new users of both PP (66.7% to 73.8%) and RLAI cohorts (59.4% to 65.0%). Meanwhile, patient satisfaction with current antipsychotic medication was maintained for continuous PP users (72.6% to 72.0%), and a decrease in satisfaction was reported for continuous RLAI users (74.3% to 66.0%).
Conclusions: These initial results demonstrate a potential long-term benefit from PP treatment. Further comparative analyses using propensity score matching are ongoing.